Literature DB >> 22307606

Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Noémi Nagy1, Mónika Adori, Abu Rasul, Frank Heuts, Daniel Salamon, Dorina Ujvári, Harsha S Madapura, Benjamin Leveau, George Klein, Eva Klein.   

Abstract

Following infection with Epstein-Barr virus (EBV), the virus is carried for life in the memory B-cell compartment in a silent state (latency I/0). These cells do not resemble the proliferating lymphoblastoid cells (LCLs) (latency III) that are generated after infection. It is of fundamental significance to identify how the different EBV expression patterns are established in the latently infected cell. In view of the prompt activatability of CD4(+) T cells in primary EBV infection, and their role in B-cell differentiation, we studied the involvement of CD4(+) T cells in the regulation of EBV latency. Lymphoblastoid cell lines (LCLs) were cocultured with autologous or allogeneic CD4(+) T cells. Activated T cells influenced the expression of two key viral proteins that determine the fate of the infected B cell. EBNA2 was down-regulated, whereas LMP1 was unregulated and the cells proliferated less. This was paralleled by the down-regulation of the latency III promoter (Cp). Experiments performed in the transwell system showed that this change does not require cell contact, but it is mediated by soluble factors. Neutralizing experiments proved that the up-regulation of LMP1 is, to some extent, mediated by IL21, but this cytokine was not responsible for EBNA2 down-regulation. This effect was partly mediated by soluble CD40L. We detected similar regulatory functions of T cells in in vitro-infected lymphocyte populations. In conclusion, our results revealed an additional mechanism by which CD4(+) T cells can control the EBV-induced B-cell proliferation.

Entities:  

Mesh:

Year:  2012        PMID: 22307606      PMCID: PMC3277165          DOI: 10.1073/pnas.1120587109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  Epstein-Barr virus: exploiting the immune system.

Authors:  D A Thorley-Lawson
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

2.  CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines.

Authors:  Katja Pokrovskaja; Barbro Ehlin-Henriksson; Csaba Kiss; Anita Challa; John Gordon; Peter Gogolak; George Klein; Laszlo Szekely
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

Review 3.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

4.  Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma.

Authors:  Henrik Hjalgrim; Karin Ekström Smedby; Klaus Rostgaard; Daniel Molin; Stephen Hamilton-Dutoit; Ellen T Chang; Elisabeth Ralfkiaer; Christer Sundström; Hans-Olov Adami; Bengt Glimelius; Mads Melbye
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

5.  STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.

Authors:  Loránd L Kis; Natalija Gerasimcik; Daniel Salamon; Emma K Persson; Noémi Nagy; George Klein; Eva Severinson; Eva Klein
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

6.  SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines.

Authors:  N Nagy; C Cerboni; K Mattsson; A Maeda; P Gogolák; J Sümegi; A Lányi; L Székely; E Carbone; G Klein; E Klein
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

7.  EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency.

Authors:  J Kurth; T Spieker; J Wustrow; G J Strickler; L M Hansmann; K Rajewsky; R Küppers
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

8.  Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.

Authors:  Barbara Savoldo; Michael L Cubbage; April G Durett; John Goss; M Helen Huls; Zhensheng Liu; Lopez Teresita; Adrian P Gee; Paul D Ling; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

9.  Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand-independent autoactivation of CD95/Fas with caspase 8-mediated apoptosis.

Authors:  Christophe Le Clorennec; Tan-Sothéa Ouk; Ibtissam Youlyouz-Marfak; Stéphanie Panteix; Catherine-Claude Martin; Julia Rastelli; Eric Adriaenssens; Ursula Zimber-Strobl; Jean Coll; Jean Feuillard; Chantal Jayat-Vignoles
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

10.  Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Authors:  Andrew D Hislop; Nicola E Annels; Nancy H Gudgeon; Alison M Leese; Alan B Rickinson
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

View more
  19 in total

Review 1.  The rise and fall of central dogmas.

Authors:  George Klein; Eva Klein
Journal:  Oncoimmunology       Date:  2016-09-26       Impact factor: 8.110

2.  T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice.

Authors:  Frank Heuts; Martin E Rottenberg; Daniel Salamon; Eahsan Rasul; Monika Adori; George Klein; Eva Klein; Noemi Nagy
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

3.  Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ.

Authors:  Ebba Sohlberg; Shanie Saghafian-Hedengren; Eahsan Rasul; Giovanna Marchini; Caroline Nilsson; Eva Klein; Noémi Nagy; Eva Sverremark-Ekström
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

4.  CD4 T cell responses in latent and chronic viral infections.

Authors:  Senta Walton; Sanja Mandaric; Annette Oxenius
Journal:  Front Immunol       Date:  2013-05-13       Impact factor: 7.561

5.  Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.

Authors:  Martin Rowe; Sweta Raithatha; Claire Shannon-Lowe
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Interleukin 21 signaling in B cells is required for efficient establishment of murine gammaherpesvirus latency.

Authors:  Christopher M Collins; Samuel H Speck
Journal:  PLoS Pathog       Date:  2015-04-13       Impact factor: 6.823

Review 7.  Epstein-Barr virus and the origin of Hodgkin lymphoma.

Authors:  Martina Vockerodt; Fathima Zumla Cader; Claire Shannon-Lowe; Paul Murray
Journal:  Chin J Cancer       Date:  2014-11-21

8.  EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency.

Authors:  Eva Klein; Noémi Nagy; Abu Eahsan Rasul
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

9.  Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2.

Authors:  Brandon Cieniewicz; Nicholas Carpino; Laurie T Krug
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.

Authors:  Eahsan Rasul; Daniel Salamon; Noemi Nagy; Benjamin Leveau; Ferenc Banati; Kalman Szenthe; Anita Koroknai; Janos Minarovits; George Klein; Eva Klein
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.